Sydney

Running trials

• Recruiting

  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

  NCT07710885· Phase 3· Source

• Active, not recruiting

  A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

  NCT06700538· Phase 1/2· Source

• Active, not recruiting

  A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

  NCT05951959· Phase 2· Source

• Active, not recruiting

  A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

  NCT05984277· Phase 3· Source

• Recruiting

  A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  NCT05536141· Phase 1· Source

• Active, not recruiting

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· Phase 3· Source

• Active, not recruiting

  A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

  NCT02972840· Phase 3· Source

• Active, not recruiting

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease

  NCT04847531· Source